GeneHarbor (Hong Kong) Biotechnologies Limited works on active pharmaceutical ingredients [API] and/or intermediates via enzymatic approach, servicing pharma manufacturing. The company has developed a proprietary platform technology for production of various enzymes. The technology aims to reduce the cost & increase the life span of the enzymes. The company is developing a novel technology for purification of monoclonal antibodies. This will facilitate the development of monoclonal antibody drugs in the future.